Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder

NCT00320736 is registered in ClinicalTrials.gov with North Suffolk Mental Health Association as lead sponsor.

NCT NCT00320736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00320736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder
Lead sponsor
North Suffolk Mental Health Association
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2004
Completion date
May 31, 2006
Enrollment
20
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia